Related Experiment Video
Updated: Jan 1, 2026

Unraveling Entropic Rate Acceleration Induced by Solvent Dynamics in Membrane Enzymes
Published on: January 16, 2016
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric
Jennifer M Chambers1, Wade Miller2, Giovanni Quichocho3
1Schrödinger , 120 West 45th Street , New York , New York 10036 , United States.
Abstract:
Point mutations in human isocitrate dehydrogenase 1 (IDH1) can drive malignancies, including lower-grade gliomas and secondary glioblastomas, chondrosarcomas, and acute myeloid leukemias. These mutations, which usually affect residue R132, ablate the normal activity of catalyzing the NADP+-dependent oxidation of isocitrate to α-ketoglutarate (αKG) while also acquiring a neomorphic activity of reducing αKG to d-2-hydroxyglutarate (D2HG). Mutant IDH1 can be selectively therapeutically targeted due to structural differences that occur in the wild type (WT) versus mutant form of the enzyme, though the full mechanisms of this selectivity are still under investigation. Here we probe the mechanistic features of the neomorphic activity and selective small molecule inhibition through a new lens, employing WaterMap and molecular dynamics simulations. These tools identified a high-energy path of water molecules connecting the inhibitor binding site with the αKG and NADP+ binding sites in mutant IDH1. This water path aligns spatially with the α10 helix from WT IDH1 crystal structures. Mutating residues at the termini of this water path specifically disrupted inhibitor binding and/or D2HG production, revealing additional key residues to consider in optimizing druglike molecules against mutant IDH1. Taken together, our findings from molecular simulations and mutant enzyme kinetic assays provide insight into how disrupting water paths through enzyme active sites can impact not only inhibitor potency but also substrate recognition and activity.
Insights
Point mutations in isocitrate dehydrogenase 1 (IDH1) drive cancers. Targeting mutant IDH1 involves understanding its neomorphic activity and inhibiting it by disrupting water paths in the enzyme
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Point mutations in human isocitrate dehydrogenase 1 (IDH1) are drivers of various malignancies.
- Mutant IDH1 gains neomorphic activity, producing D-2-hydroxyglutarate (D2HG), and loses normal catalytic function.
- Selective therapeutic targeting of mutant IDH1 is a promising strategy.
Purpose of the Study:
- To investigate the mechanistic features of mutant IDH1's neomorphic activity.
- To explore selective small molecule inhibition of mutant IDH1 using novel computational approaches.
- To identify key residues and mechanisms for optimizing drug design against mutant IDH1.
Main Methods:
- Employed WaterMap and molecular dynamics simulations to analyze mutant IDH1.
- Identified a high-energy water molecule path connecting inhibitor and substrate binding sites.
- Utilized mutant enzyme kinetic assays and site-directed mutagenesis.
Main Results:
- A water path connecting inhibitor and α-ketoglutarate (αKG)/NADP+ binding sites was identified in mutant IDH1.
- Mutations at the water path termini disrupted inhibitor binding and/or D2HG production.
- Findings reveal the role of water paths in enzyme activity and inhibitor interactions.
Conclusions:
- Disrupting water paths is a viable strategy for inhibiting mutant IDH1.
- Identified key residues for optimizing druglike molecules targeting mutant IDH1.
- Provides mechanistic insights into mutant IDH1 inhibition and substrate recognition.
More Related Videos
Related Concept Videos
Allosteric Regulation
Enzyme Inhibition
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...

